Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Transkaryotic Factor VIII gene therapy: Beth Israel Deaconess Medical Center (Boston, Mass.) resumed TKTX's 12-patient Phase I safety study, which had been susp

Transkaryotic Therapies Inc. (TKTX), Cambridge, Mass.
Product: Transkaryotic Factor VIII

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE